TNF related apoptosis inducing ligand TRAIL A new path to anti cancer therapies英文文献.pdfVIP

European Journal of Pharmacology 625 (2009) 63–72 Contents lists available at ScienceDirect European Journal of Pharmacology journal homepage: www.el sevier.c om/l o cate/ ejphar Review TNF-related apoptosis-inducing ligand (TRAIL): A new path to anti-cancer therapies Peter A. Holoch a, Thomas S. Griffith a,b,c,⁎ a Department of Urology, University of Iowa, 375 Newton Road, Iowa City, IA 52242, United States b Interdisciplinary Graduate Program in Immunology, University of Iowa,375 Newton Road, Iowa, City, IA 52242, United States c The Prostate Cancer Research Program of the Holden Comprehensive Cancer Center, University of Iowa, 375 Newton Road, Iowa City, IA 52242, United States a r t i c l e i n f o a b s t r a c t Article history: Since its discovery in 1995, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), a member of the Received 1 May 2009 tumor necrosis factor super family, has been under intense focus because of its remarkable ability to induce Received in revised form 8 June 2009 apoptosis in malignant human cells while leaving normal cells unscathed. Consequently, activation of the Accepted 22 June 2009 apoptotic signaling pathway from the death-inducing TRAIL receptors provides an attractive, biologically- Available online 18 October 2009 targeted approach to cancer therapy. A great deal of research has focused on deciphering the TRAIL receptor